Cargando…

Aspirin Use for Primary Cardiovascular Prevention During the COVID-19 Pandemic

Detalles Bibliográficos
Autor principal:	Siegel, Arthur J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054638/ https://www.ncbi.nlm.nih.gov/pubmed/33888225 http://dx.doi.org/10.1016/j.amjmed.2020.11.008

Ejemplares similares

Use of aspirin for primary prevention in patients with diabetes during the COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2021)

Should Aspirin Be Used for the Primary Prevention of Cardiovascular Disease in the General Population?
por: Huang, Qing-Yu, et al.
Publicado: (2015)

Which people should take aspirin for primary prevention of cardiovascular disease?
por: Lozano, Roberto, et al.
Publicado: (2015)

Use and Misuse of Aspirin in Primary Cardiovascular Prevention
por: Coccheri, Sergio
Publicado: (2017)

Aspirin for primary prevention of cardiovascular disease
por: Nansseu, Jobert Richie N., et al.
Publicado: (2015)

Aspirin for Primary Prevention of Cardiovascular Disease
por: Kim, Ji Hye, et al.
Publicado: (2019)

Use of Aspirin and Statin as primary prevention for cardiovascular diseases
por: Alkhail, Bahaa Aba, et al.
Publicado: (2016)

Aspirin Therapy in COVID-19: Prevention of NETosis
por: Kow, Chia Siang, et al.
Publicado: (2023)

Aspirin overutilization for the primary prevention of cardiovascular disease
por: VanWormer, Jeffrey J, et al.
Publicado: (2014)

Aspirin Bioactivity for Prevention of Cardiovascular Injury in COVID-19
por: Diaz, Temistocles, et al.
Publicado: (2020)

Aspirin in primary prevention of cardiovascular disease in diabetes
por: Papazafiropoulou, Athanasia K., et al.
Publicado: (2021)

Aspirin for primary prevention of cardiovascular disease in diabetes
por: Xing, Ying, et al.
Publicado: (2019)

Aspirin for the primary prevention of cardiovascular disease in the elderly
por: O’Sullivan, Jack W
Publicado: (2019)

Response to Aspirin Therapy in COVID-19: Prevention of NETosis
por: Lal, Amos, et al.
Publicado: (2023)

Can pre-race aspirin prevent sudden cardiac death during marathons?
por: Siegel, Arthur J, et al.
Publicado: (2017)

Prescribing Aspirin for Preeclampsia Prevention in Pregnant Women During COVID-19: Should or Shouldn’t?
por: Eslamian, Laleh, et al.
Publicado: (2021)

Aspirin for Primary Prevention of Cardiovascular Diseases: “WALTZ” with the Evidence
por: Dimitriadis, Kyriakos, et al.
Publicado: (2022)

Aspirin for Prevention of Cardiovascular Disease
por: Mendy, Vincent L., et al.
Publicado: (2017)

Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease
por: Chen, Yinong, et al.
Publicado: (2021)

The enigma of cardiovascular diseases during the COVID-19 pandemic
por: Jadali, Zohreh
Publicado: (2022)

The Effects of The COVID-19 Pandemic on Primary Prevention
por: Spindel, Jeffrey F, et al.
Publicado: (2022)

Use of Aspirin for Primary and Secondary Cardiovascular Disease Prevention in the United States, 2011–2012
por: Mainous, Arch G., et al.
Publicado: (2014)

Accuracy of Electronic Health Record–Documented Aspirin for Primary Prevention in Adult Outpatients
por: Chipalkatti, Naina, et al.
Publicado: (2023)

Aspirin Resistance in Obese and Elderly Patients with COVID-19?
por: Chiang, Kate Chander, et al.
Publicado: (2021)

Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease
por: Dai, Yuxiang, et al.
Publicado: (2012)

Aspirin use for cardiovascular disease prevention in the uninsured population
por: Liu, Nina, et al.
Publicado: (2020)

Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach
por: Cofer, Lucas B., et al.
Publicado: (2022)

Aspirin for primary prevention in the elderly
por: Saad, Marwan, et al.
Publicado: (2019)

Aspirin in primary prevention: USPSTF recommendations
por: Aalbers, J
Publicado: (2010)

Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis
por: Stegeman, Inge, et al.
Publicado: (2015)

The Efficacy And Safety Of Aspirin As The Primary Prevention Of Cardiovascular Disease: An Updated Meta-Analysis
por: Xie, Wenchao, et al.
Publicado: (2019)

Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
por: Noubiap, Jean Jacques N, et al.
Publicado: (2015)

Cost‐Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease
por: Michaud, Tzeyu L., et al.
Publicado: (2015)

Prerace aspirin to protect susceptible runners from cardiac arrest during marathons: is opportunity knocking?
por: Siegel, Arthur J
Publicado: (2015)

Aspirin in the Modern Era of Cardiovascular Disease Prevention
por: Murphy, Ella, et al.
Publicado: (2021)

Increased Cardiovascular Mortality in Ecuador during COVID-19 Pandemic
por: Fornasini, Marco, et al.
Publicado: (2023)

A 16-Month Community-Based Intervention to Increase Aspirin Use for Primary Prevention of Cardiovascular Disease
por: Oldenburg, Niki C., et al.
Publicado: (2014)

Aspirin for primary prevention of stroke in individuals without cardiovascular disease—A meta-analysis
por: Judge, Conor, et al.
Publicado: (2019)

Primary prevention of myocardial infarction: aspirin is not as useful as it seems
por: Luan, Yi, et al.
Publicado: (2020)

Aspirin in primary prevention: who is the target?
por: Gatto, Laura, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hu7v0vdcpk9cttiblgh65ikqqf